Drug Targets – Products

Sino Biological is at the forefront of accelerating Mpox research, offering a comprehensive portfolio of MPXV proteins and antibodies.

On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics' ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S.

Milestone payment follows successful target identification and validation in separate project under same collaboration.

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering.

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

CatSci Ltd are thrilled to announce that they have won a Welsh Government SMART Capital Equipment Fund grant to enhance their oligonucleotides capability and offer more and better R&D and manufacturing solutions to customers.

Cresset, announces a collaboration with Enamine to develop innovative new solutions for the early drug discovery process.

Novel GHz-class NMR systems are enabling unprecedented life science and materials research in functional structural biology, drug discovery, metabolomics and cleantech
research.